scholarly journals A NIR-I light-responsive superoxide radical generator with cancer cell membrane targeting ability for enhanced imaging-guided photodynamic therapy

2020 ◽  
Vol 11 (37) ◽  
pp. 10279-10286 ◽  
Author(s):  
Yingcui Bu ◽  
Tianren Xu ◽  
Xiaojiao Zhu ◽  
Jie Zhang ◽  
Lianke Wang ◽  
...  

A NIR-I light initiated theranostic system based on photosensitizer EBD-1 with cancer cell membrane targeting ability, which can self-report cell viability.

Biomaterials ◽  
2017 ◽  
Vol 142 ◽  
pp. 149-161 ◽  
Author(s):  
Shi-Ying Li ◽  
Hong Cheng ◽  
Wen-Xiu Qiu ◽  
Lu Zhang ◽  
Shuang-Shuang Wan ◽  
...  

2020 ◽  
Vol 12 (1) ◽  
Author(s):  
Hanyi Fang ◽  
Mengting Li ◽  
Qingyao Liu ◽  
Yongkang Gai ◽  
Lujie Yuan ◽  
...  

AbstractTriple-negative breast cancer (TNBC) is a subtype of breast cancer in which the estrogen receptor and progesterone receptor are not expressed, and human epidermal growth factor receptor 2 is not amplified or overexpressed either, which make the clinical diagnosis and treatment very challenging. Molecular imaging can provide an effective way to diagnose TNBC. Upconversion nanoparticles (UCNPs), are a promising new generation of molecular imaging probes. However, UCNPs still need to be improved for tumor-targeting ability and biocompatibility. This study describes a novel probe based on cancer cell membrane-coated upconversion nanoparticles (CCm-UCNPs), owing to the low immunogenicity and homologous-targeting ability of cancer cell membranes, and modified multifunctional UCNPs. This probe exhibits excellent performance in breast cancer molecular classification and TNBC diagnosis through UCL/MRI/PET tri-modality imaging in vivo. By using this probe, MDA-MB-231 was successfully differentiated between MCF-7 tumor models in vivo. Based on the tumor imaging and molecular classification results, the probe is also expected to be modified for drug delivery in the future, contributing to the treatment of TNBC. The combination of nanoparticles with biomimetic cell membranes has the potential for multiple clinical applications.


2017 ◽  
Vol 27 (25) ◽  
pp. 1700220 ◽  
Author(s):  
Li-Han Liu ◽  
Wen-Xiu Qiu ◽  
Yao-Hui Zhang ◽  
Bin Li ◽  
Chi Zhang ◽  
...  

2019 ◽  
Vol 9 (1) ◽  
pp. 1901100 ◽  
Author(s):  
Wen Ma ◽  
Sui‐Nan Sha ◽  
Pei‐Ling Chen ◽  
Meng Yu ◽  
Jian‐Jun Chen ◽  
...  

2020 ◽  
Vol 55 (18) ◽  
pp. 7843-7856 ◽  
Author(s):  
Pei-Ling Chen ◽  
Qun-Ying Shi ◽  
Tian Chen ◽  
Ping Wang ◽  
Yun Liu ◽  
...  

ACS Nano ◽  
2017 ◽  
Vol 11 (7) ◽  
pp. 7006-7018 ◽  
Author(s):  
Shi-Ying Li ◽  
Hong Cheng ◽  
Bo-Ru Xie ◽  
Wen-Xiu Qiu ◽  
Jing-Yue Zeng ◽  
...  

Cancers ◽  
2021 ◽  
Vol 13 (16) ◽  
pp. 4109
Author(s):  
Elise Thécua ◽  
Laurine Ziane ◽  
Guillaume Paul Grolez ◽  
Alexandre Fagart ◽  
Abhishek Kumar ◽  
...  

Photodynamic therapy (PDT) appears to be a promising strategy in biomedical applications. However, the complexity of its parameters prevents wide acceptance. This work presents and characterizes a novel optical device based on knitted light-emitting fabrics and dedicated to in vitro PDT involving low irradiance over a long illumination period. Technical characterization of this device, called CELL-LEF, is performed. A cytotoxic study of 5-ALA-mediated PDT on human cancer cell lines is provided as a proof of concept. The target of delivering an irradiance of 1 mW/cm2 over 750 cm2 is achieved (mean: 0.99 mW/cm2; standard deviation: 0.13 mW/cm2). The device can maintain a stable temperature with the mean thermal distribution of 35.1 °C (min: 30.7 °C; max: 38.4 °C). In vitro outcomes show that 5-ALA PDT using CELL-LEF consistently and effectively induced a decrease in tumor cell viability: Almost all the HepG2 cells died after 80 min of illumination, while less than 60% of U87 cell viability remained. CELL-LEF is suitable for in vitro PDT involving low irradiance over a long illumination period.


2018 ◽  
Vol 6 (7) ◽  
pp. 1834-1845 ◽  
Author(s):  
Jiong Li ◽  
Xuandong Wang ◽  
Dongye Zheng ◽  
Xinyi Lin ◽  
Zuwu Wei ◽  
...  

A photosensitizer-loaded magnetic nanobead with surface coated with a cancer cell membrane to enhance MR/NIR fluorescence imaging and PDT efficacy.


Molecules ◽  
2021 ◽  
Vol 26 (19) ◽  
pp. 5990
Author(s):  
Yuan Xu ◽  
Yang Tan ◽  
Xiuqin Ma ◽  
Xiaoyi Jin ◽  
Ye Tian ◽  
...  

Photodynamic therapy (PDT) represents an effective treatment to cure cancer. The targeting ability of the photosensitizer is of utmost importance. Photosensitizers that discriminate cancer cells can avoid the killing of normal cells and improve PDT efficacy. However, the design and synthesis of photosensitizers conjugated with a recognition unit of cancer cell markers is complex and may not effectively target cancer. Considering that the total RNA content in cancer cells is commonly higher than in normal cells, this study has developed the photosensitizer QICY with RNA-targeting abilities for the discrimination of cancer cells. QICY was specifically located in cancer cells rather than normal cells due to their stronger electrostatic interactions with RNA, thereby further improving the PDT effects on the cancer cells. After intravenous injection into mice bearing a xenograft tumor, QICY accumulated into the tumor location through the enhanced permeability and retention effect, automatically targeted cancer cells under the control of RNA, and inhibited tumor growth under 630 nm laser irradiation without obvious side effects. This intelligent photosensitizer with RNA-targeting ability not only simplifies the design and synthesis of cancer-cell-targeting photosensitizers but also paves the way for the further development of highly efficient PDTs.


Sign in / Sign up

Export Citation Format

Share Document